| Name | Title | Contact Details |
|---|---|---|
Lucas Donigian |
Vice President, Head of Business Development and Commercial | Profile |
Bijal Desai |
Vice President of Finance and Strategy | Profile |
Laura O`Connor |
Vice President of Human Resources and Diversity, Equity, and Inclusion | Profile |
Neil Klompas |
Chief Operating Officer and Chief Financial Officer | Profile |
Prem Girn |
Senior Director and Human Resources Business Partner | Profile |
Arizona Benefit Plans is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CalciMedica is a privately-held, clinical stage biotechnology company focused on CRAC channel drug discovery and development for the treatment of acute and chronic inflammatory diseases.
Ventana Clinical Research Corp is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Adventus Group is a Freeport, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market. We follow strict Standard Operating Protocols and adhere to the Law`s of Canada and Foreign Jurisdictions. Abattis Bioceuticals Corp. aims to become a leader in the growing, testing, and distribution of medical and adult-use cannabis in North America. Through its network of subsidiaries and partners, the company has developed an innovative GDERS (grow, dry, extract, refine, sell) strategy spanning the entire industry supply chain from seed to sale. These subsidiaries and partners specialize in cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment, and consulting services across the continent. The company follows strict standard operating protocols and adheres to both U.S. and Canadian laws pertaining to the cultivation, testing, and sale of cannabis.